Immunization of young infants with Edmonston-Zagreb measles vaccine.
Recently studies conducted in several countries using Edmonston-Zagreb vaccine administered subcutaneously to infants younger than 9 months of age have shown high seroconversion rates, approaching or equaling those routinely achieved at 9 months of age with the more widely used Schwarz vaccine. These results have raised expectations that the Edmonston-Zagreb vaccine can play an important role in helping to prevent measles in young infants in highly endemic areas. Because of the implications of changing the measles vaccine recommendations, vaccine advisory groups and vaccine manufacturers will require additional studies to confirm the preliminary findings and to answer new questions which have been raised. The needed data will probably be collected over the next year or two in studies already under way or being planned in the hope that a more effective vaccine for young infants can be introduced before the end of this decade.
Markowitz
L E
LE
Division of Immunization, Centers for Disease Control, Atlanta, GA 30333.
Bernier
R H
RH
D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D006801:Humans; D007223:Infant; D008457:Measles / Q000276:immunology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage / Q000276:immunology; D014611:Vaccination
D000914:Antibodies, Viral; D008458:Measles Vaccine